Methods of improving adeno-associated viral transduction
AssigneeuniQure IP B.V.
InventorValerie Ferreira
Life of this patent
Estimating the term…
Abstract
Described herein are saturating agents, AAV gene therapy vectors, and therapeutic agents, as well as methods and kits comprising the same.
Claims8
A method of treating a human subject, comprising administering an adeno-associated virus (AAV) gene therapy vector to a human subject having been administered a saturating agent comprising soybean oil, egg yolk phospholipids, glycerine, and water, wherein the saturating agent is taken up by the reticuloendothelial system (RES), wherein transduction efficiency of the AAV gene therapy vector is increased at least 3 fold for 35 days post administration compared to the transduction efficiency in the absence of the saturating agent.
Dependencies are inferred from the claim text.